Actinium Pharmaceuticals (ATNM) Current Assets (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Current Assets of $43.3 million for Q1 2026, down 34.9% year-over-year from $66.5 million in Q1 2025, and down 12.39% quarter-over-quarter from $49.4 million in Q4 2025.
Actinium Pharmaceuticals (ATNM) Current Assets (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Current Assets for 17 consecutive years, with $43.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 34.9% year-over-year to $43.3 million; the TTM figure through Mar 2026 stood at $43.3 million (down 34.9% YoY), while the FY2025 annual figure was $49.4 million, down 33.72% from the prior year.
- Current Assets eased to $43.3 million in Q1 2026 per ATNM's latest filing, from $49.4 million in the prior quarter.
- Across five years, Current Assets topped out at $118.3 million in Q2 2022 and bottomed at $43.3 million in Q1 2026.
- Historically, Current Assets has averaged $80.9 million across 5 years, with a median of $79.5 million in 2024.
- Annual changes were most pronounced in 2022 — Current Assets surged 42.23% — and 2026, when it tumbled 34.9%.
- Actinium Pharmaceuticals' Current Assets stood at $110.9 million in 2022, then declined by 29.46% to $78.3 million in 2023, then decreased by 4.8% to $74.5 million in 2024, then sank by 33.72% to $49.4 million in 2025, then slipped by 12.39% to $43.3 million in 2026.
- Business Quant data shows ATNM's Current Assets at $43.3 million in Q1 2026, $49.4 million in Q4 2025, and $54.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 1.76 Bn |
| 10 | Actinium Pharmaceuticals | 35.79 Mn | 35.79 Mn | - | 37.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.74 Mn |
| Mar 31, 2026 | 43.26 Mn |
| Dec 31, 2025 | 49.38 Mn |
| Sep 30, 2025 | 54.37 Mn |
| Jun 30, 2025 | 61.03 Mn |
| Mar 31, 2025 | 66.46 Mn |
| Dec 31, 2024 | 74.51 Mn |
| Sep 30, 2024 | 79.52 Mn |
| Jun 30, 2024 | 87.07 Mn |
| Mar 31, 2024 | 85.37 Mn |
| Dec 31, 2023 | 78.26 Mn |
| Sep 30, 2023 | 85.60 Mn |
| Jun 30, 2023 | 95.54 Mn |
| Mar 31, 2023 | 98.55 Mn |
| Dec 31, 2022 | 110.94 Mn |
| Sep 30, 2022 | 113.42 Mn |
| Jun 30, 2022 | 118.30 Mn |
| Mar 31, 2022 | 74.05 Mn |
| Dec 31, 2021 | 79.75 Mn |
| Sep 30, 2021 | 83.26 Mn |